Botanical species · safety record

Turbina corymbosa

The EFSA Compendium of Botanicals holds 9 constituent measurements and 1 adverse-effect record for Turbina corymbosa. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Turbina corymbosa (L.) Raf.

9Constituent measurements

1Safety records

3Cited sources

0Licensed products (Canada)

Also recorded as

Rivea corymbosa (L.) Hallier.f.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Ergoline alkaloids	Stem / stalk	Solvent extraction	≥ 0.01 Percent	Fluorimetry, Nephelometry and Polarimetry	Resolve DOI
Ergoline alkaloids	Stem / stalk	Solvent extraction	≤ 0.012 Percent	Fluorimetry, Nephelometry and Polarimetry	Resolve DOI
Ergoline alkaloids	Leaves	Solvent extraction	≤ 0.027 Percent	Fluorimetry, Nephelometry and Polarimetry	Resolve DOI
Ergoline alkaloids	Leaves	Solvent extraction	≥ 0.016 Percent	Fluorimetry, Nephelometry and Polarimetry	Resolve DOI
Chanoclavine-1	Seed	—	5e-04 Percent	—	No resolvable identifier
Elymoclavine	Seed	—	5e-04 Percent	—	No resolvable identifier
Ergine	Seed	—	0.002 Percent	—	No resolvable identifier
Ergine	Seed	—	0.0065 Percent	—	No resolvable identifier
Lysergol	Seed	—	5e-04 Percent	—	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Neurotoxicity	Neurologic: central nervous system	Seed	—	Human (as organism)	Case report	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

ISBELL, H., GORODETZKY, CW. EFFECT OF ALKALOIDS OF OLOLIUQUI IN MAN. Psychopharmacologia, 1966, vol. 8, no. 5, p. 331-331.
Farnsworth, Norman R. Hallucinogenic plants. Science (washington, dc, united states), 1968, vol. 162, no. 3858, p. 1086-92.
TABER, WA., HEACOCK, RA., MAHON, ME. ERGOT-TYPE ALKALOIDS IN VEGETATIVE TISSUE OF RIVEA-CORYMBOSA (L) HALL F. Phytochemistry, 1963, vol. 2, no. 1, p. 99-101. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature